Mission Statement

The HPTN is dedicated to the discovery and development of new and innovative research strategies to reduce the acquisition and transmission of HIV.

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection.

The HPTN research agenda is focused primarily on the use of integrated strategies: use of antiretroviral drugs (antiretroviral therapy and pre-exposure prophylaxis); interventions for substance abuse, particularly injection drug use; behavioral risk reduction interventions and structural interventions. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.

The HPTN was established in 2000, building on the work of the HIV Network for Prevention Trials (HIVNET). HPTN’s Leadership and Operations Center (LOC), is based at FHI 360, Durham, North Carolina. Its Laboratory Center (LC) is at Johns Hopkins University, Baltimore, Maryland and its Statistical and Data Management Center (SDMC) is housed within the Statistical Center for HIV/AIDS Research and Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The HPTN Modelling Centre, part of the SDMC, is a collaboration between the Department of Infectious Diseases Epidemiology at Imperial College London and SCHARP.

HPTN receives its funding from three NIH institutes: the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health and the National Institute on Drug Abuse.

Webinars

The HPTN Leadership and Operations Center (LOC)

The HPTN Statistical and Data Management Center (SDMC)


Conversations with the HPTN

Gertrude Nanyonjo, an HPTN 084 Community Working Group member, is the community engagement lead and a senior social sciences coordinator at UVRI-IAVI HIV Vaccine Program in Entebbe, Uganda. She initially worked on an HIV prevention program focusing on youth and adolescents at risk of acquiring HIV in a busy rural center in Southwestern Uganda (Rakai District), where the first HIV case was identified. Nanyonjo has been active in HIV prevention clinical trials and socio-behavioral studies.

Pearson M'modzi is a senior community research officer at UNC Project Lilongwe in Malawi. He has been a lead community educator for the AMP studies (HVTN 703/HPTN 081 and HVTN 704/HPTN 085) and HPTN 084 (LIFE). Pearson also serves as a community working group representative for HPTN 084 and a member of the HPTN Community Working Group Steering Committee.   

Doreen Kemigisha, MPH, a member of the HPTN Community Working Group (CWG), is a senior health visitor, community educator, and qualitative coordinator at Makerere University – John Hopkins University (MU-JHU) Research Collaboration based at Mulago Hospital Complex in Kampala, Uganda. She has worked with MU-JHU since 2009, carrying out participant recruitment and retention activities for the HPTN and the Microbicide Trials Network.

Rona Siskind is a health specialist at the U.S. National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS) in Bethesda, Md., focusing on community engagement, training, and communications related primarily to HIV vaccine and prevention research. She has been at DAIDS for more than 30 years and has worked with all the HIV/AIDS clinical trials research networks. Since early in her tenure at DAIDS, she has worked with, and on behalf of, the networks’ community working groups and advisory boards.